# To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants

> **NCT07505030** · PHASE1 · NOT_YET_RECRUITING · sponsor: **LyncBio Therapeutics Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- UC - Ulcerative Colitis

## Interventions

- **DRUG:** LYNC-101
- **DRUG:** LYNC-101 Placebo

## Key facts

- **NCT ID:** NCT07505030
- **Lead sponsor:** LyncBio Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-25
- **Primary completion:** 2027-03-19
- **Final completion:** 2027-04-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07505030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07505030, "To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07505030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*